Abstract
In the early 1970s, the hypothesis that tumor growth is dependent on angiogenesis was first established [1]. Since then, the role played by blood vessels in tumor growth and progression has been extensively studied and debated. Preclinical evidence strongly suggests that VEGF plays a role in promoting the growth and progression of disease in various tumor types including squamous cell carcinoma of the head and neck (SCCHN), of which close to 38,500 new cases are diagnosed each year. In SCCHN, the role of antiangiogenic therapy has yet to be defined. Traditional therapy of SCCHN has involved a multimodality approach with radiotherapy, surgery as well as chemotherapy. More recently, novel therapeutic agents have been subject to preclinical and clinical development, among which anti-angiogenic therapy has gained much recent interest. In this critical review, we give an overview of angiogenesis and its potential therapeutic targets, and we focus on its preclinical and clinical applications in SCCHN.
Keywords: Angiogenesis, head and neck, endothelial, VEGF, targeted therapy, squamous cell carcinoma, endothelial growth factor, antiangiogenesis
Current Cancer Drug Targets
Title: Targeting Angiogenesis in Head and Neck Cancer
Volume: 7 Issue: 7
Author(s): Nabil F. Saba, Dong M. Shin and Fadlo R. Khuri
Affiliation:
Keywords: Angiogenesis, head and neck, endothelial, VEGF, targeted therapy, squamous cell carcinoma, endothelial growth factor, antiangiogenesis
Abstract: In the early 1970s, the hypothesis that tumor growth is dependent on angiogenesis was first established [1]. Since then, the role played by blood vessels in tumor growth and progression has been extensively studied and debated. Preclinical evidence strongly suggests that VEGF plays a role in promoting the growth and progression of disease in various tumor types including squamous cell carcinoma of the head and neck (SCCHN), of which close to 38,500 new cases are diagnosed each year. In SCCHN, the role of antiangiogenic therapy has yet to be defined. Traditional therapy of SCCHN has involved a multimodality approach with radiotherapy, surgery as well as chemotherapy. More recently, novel therapeutic agents have been subject to preclinical and clinical development, among which anti-angiogenic therapy has gained much recent interest. In this critical review, we give an overview of angiogenesis and its potential therapeutic targets, and we focus on its preclinical and clinical applications in SCCHN.
Export Options
About this article
Cite this article as:
Saba F. Nabil, Shin M. Dong and Khuri R. Fadlo, Targeting Angiogenesis in Head and Neck Cancer, Current Cancer Drug Targets 2007; 7 (7) . https://dx.doi.org/10.2174/156800907782418356
DOI https://dx.doi.org/10.2174/156800907782418356 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Approaches to Target Cancer Stem Cells: Current Scenario
Mini-Reviews in Medicinal Chemistry The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer
Reviews on Recent Clinical Trials Advances and Perspectives in Cancer Nanotherapy: The Added- Value of Nanocarriers
Current Nanomedicine The Cross-over of Anticancer Agents with Osteoclast Activities
Current Cancer Therapy Reviews Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy
Current Pharmaceutical Biotechnology Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Current Topics in Medicinal Chemistry Protective Effects of Corticosteroids and Neurosteroids on Cochlear injury
Medicinal Chemistry HPV as a Model for the Development of Prophylactic and Therapeutic Cancer Vaccines
Current Molecular Medicine Pathogenesis of SLE Dermatitis - A Reflection of the Process in SLE Nephritis?
Current Rheumatology Reviews Synthesis, Photophysical and Photochemical Aspects of Phthalocyanines for Photodynamic Therapy
Current Organic Chemistry Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 2- Application to Head-and-Neck Cancer Patients
Clinical Cancer Drugs The Fate of Nanoparticles In Vivo and the Strategy of Designing Stealth Nanoparticle for Drug Delivery
Current Drug Targets Applications of Computed Tomography, Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy for Planning External Beam Radiotherapy
Current Medical Imaging Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology The Role of Pemetrexed in Lung Adenocarcinoma, Mixed Subtype with Bronchioloalveolar Carcinoma Features
Current Drug Targets Angiogenesis Inhibitors: Current & Future Directions
Current Pharmaceutical Design Synthesis, Preferentially Hypoxic Apoptosis and Anti-Angiogenic Activity of 3- Amino-1,2,4-Benzotriazine-1,4-Dioxide Bearing Alkyl Linkers with a 3-Amino-1,2,4- Benzotriazine-1-Oxide Moiety
Anti-Cancer Agents in Medicinal Chemistry Drugs of Abuse: Epigenetic Mechanisms in Toxicity and Addiction
Current Medicinal Chemistry